Axitinib-Induced Hypothyroidism as a Predictor of Long-Term Survival in Patients with Metastatic Renal Cell Carcinoma

Abstract

Background: The side effects of sunitinib, namely onset of hypertension and hypothyroidism, have been reported to be predictive biomarkers of treatment efficacy. However, the relationship between hypothyroidism and prolongation of survival in treatment with axitinib, a drug similar to sunitinib, has not yet been reported. Objective: In this study, we examined the relationship between the onset of hypothyroidism caused by axitinib and overall survival (OS) and progression-free survival (PFS). Methods: In this retrospective study, 44 Japanese patients, including 30 men and 14 women, were enrolled. The average age of subjects in this study was 67 years. Results: During treatment, 68% of patients developed hypothyroidism, with an average peak thyroid-stimulating hormone (TSH) value of 15.7 mIU/L. Patients with TSH > 4 mIU/L and required thyroid hormone regulation with levothyroxine had prolonged PFS (11.1 vs. 3.5 months; p = 0.002) and OS (26.4 vs. 15.6 months; p = 0.02). Hypothyroidism was found to be a significant side effect of axitinib in patients with metastatic renal cell carcinoma (mRCC). Patients with hypothyroidism had significantly longer PFS and OS. Conclusion: Our findings indicate that hypothyroidism may be a predictive marker of therapeutic effect of axitinib against mRCC.

Prognostic value of hypothyroidism in patients undergoing intensity‐modulated radiation therapy for nasopharyngeal carcinoma

“…Various studies on cancer have associated hypothyroidism with a better prognosis 6–8 . However, there have been contradictory reports that hypothyroidism was an independent risk factor for poor prognosis 21 .…”

“…Various studies on cancer have associated hypothyroidism with a better prognosis. [6][7][8] However, there have been contradictory reports that hypothyroidism was an independent risk factor for poor prognosis. 21 According to a study on head and neck cancer by Nelson et al, 9 the hypothyroid cases performed better in terms of recurrence-free survival rate than the euthyroid cases.…”

“…Chemotherapy has been shown to increase the sensitivity to radiotherapy and increase radiation‐induced hypothyroidism 5 . Further, studies have shown that hypothyroidism has been associated with improved prognoses in various tumors, such as liver, kidney, and metastatic cancers 6–8 . For head and neck cancer, patients who developed hypothyroidism reportedly had a higher recurrence‐free survival rate than those who did not develop hypothyroidism 9 .…”

“…5 Further, studies have shown that hypothyroidism has been associated with improved prognoses in various tumors, such as liver, kidney, and metastatic cancers. [6][7][8] For head and neck cancer, patients who developed hypothyroidism reportedly had a higher recurrence-free survival rate than those who did not develop hypothyroidism. 9 However, to the best of our knowledge, there has been no report describing the prognostic value of hypothyroidism in patients with NPC thus far.…”

Διερεύνηση Των Ορμονικών Επιπέδων Σε Ασθενείς Με Μεταστατικό Καρκίνο Του Νεφρού Υπό Στοχευμένες Θεραπείες

“…Έτσι, δεν κρίνεται απαραίτητη ούτε η μείωση ούτε η διακοπή της θεραπείας [273,274,278]. Άλλοι παράγοντες που προκαλούν υποθυρεοειδισμό είναι το sorafenib, το imatinib, το nilotinib, το axitinib και το pazopanib [279,280,281,282,283].…”